Intensity Therapeutics
INTS
35 hedge funds and large institutions have $1.63M invested in Intensity Therapeutics in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
125% more capital invested
Capital invested by funds: $721K → $1.63M (+$904K)
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
35% more funds holding
Funds holding: 26 → 35 (+9)
0.03% more ownership
Funds ownership: 0.24% → 0.27% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$159K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$81.7K |
| 3 |
Corient Private Wealth
Miami,
Florida
|
+$81.1K |
| 4 |
LA
Legacy Advisors
Plymouth Meeting,
Pennsylvania
|
+$62.2K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$58.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sapient Capital
Indianapolis,
Indiana
|
-$132K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$45K |
| 3 |
Citigroup
New York
|
-$18K |
| 4 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$6K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$5.17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCA
26
Sassicaia Capital Advisers
Jericho,
New York
| $6.15K | -$2.03K | -200 | -25% |
|
|
MG
27
Marex Group
London,
| $6.15K | +$6.08K | +600 | New |
|
|
TC
28
T3 Companies
New York
| $5.58K | +$5.52K | +544 | New |
|
29
Vontobel Holding
Zurich,
Switzerland
| $4.86K | +$4.87K | +480 | New |
|
|
BPA
30
Beacon Pointe Advisors
Newport Beach,
California
| $4.18K | +$4.14K | +408 | New |
|
|
WIA
31
World Investment Advisors
Santa Barbara,
California
| $4.1K | +$4.06K | +400 | New |
|
32
CIBC Private Wealth Group
Atlanta,
Georgia
| $2.06K | +$10 | +1 | +0.5% |
|
33
Bank of America
Charlotte,
North Carolina
| $240 | -$20 | -2 | -8% |
|
34
Morgan Stanley
New York
| $205 | – | – | – |
|
|
35
Citigroup
New York
| $36 | -$18K | -1,779 | -100% |
|
|
SRL
36
Scientech Research LLC
Jersey City,
New Jersey
| – | -$6K | -989 | Closed |
|
INTS Hedge Fund Activity: Q4 2025 in Review
35 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q4 2025, worth a combined $1.63M — up 125% from $721K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new INTS positions and 1 closed out — a net gain of 9 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $159K. The largest seller was Sapient Capital, cutting an estimated $132K.
- 35 institutional investors held Intensity Therapeutics (INTS) as of Q4 2025, up from 26 in Q3 2025.
- Funds reported $1.63M of Intensity Therapeutics stock for Q4 2025, up 125% quarter-over-quarter.
- 10 funds opened new Intensity Therapeutics positions in Q4 2025 and 1 closed out, a net change of +9 holders.
- The largest Intensity Therapeutics buyer in Q4 2025 was Vanguard Group, an estimated $159K added.
- The largest Intensity Therapeutics seller in Q4 2025 was Sapient Capital, an estimated $132K sold.
Based on aggregated 13F filings for Q4 2025.